In the context of leukemia, overexpression of hsa-miR-181b-5p was shown to enhance proliferation in acute myeloid leukemia by targeting MLK2. Furthermore, hsa-miR-92b-3p was identified as an oncomiR in glioblastoma by targeting SMAD321, which is known to be lost in several cases of pediatric T-ALL22, and PTEN23, a well-established T-ALL oncosuppressor24, 25. The gene discussed is MAP3K10; the disease is glioblastoma.